1 |
Yaksh TL, Rudy TA: Analgesia mediated by a direct spinal action of narcotics. Science 1976; 192: 1357-8
DOI
PUBMED
|
2 |
Paice JA, Penn RD, Shott S: Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Symptom Manage 1996; 11: 71-80
DOI
ScienceOn
|
3 |
Smith HS, Deer TR, Staats PS, Singh V, Sehgal N, Cordner H: Intrathecal drug delivery. Pain Physician 2008; 11(Suppl): 89-104
ScienceOn
|
4 |
Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, et al: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 2004; 291: 63-70
DOI
ScienceOn
|
5 |
Deer TR, Caraway DL, Kim CK, Dempsey CD, Stewart CD, McNeil KF: Clinical experience with intrathecal bupivacaine in combination with opioid for the treatment of chronic pain related to failed back surgery syndrome and metastatic cancer pain of the spine. Spine J 2002; 2: 274-8
DOI
ScienceOn
|
6 |
Classen AM, Wimbish GH, Kupiec TC: Stability of admixture containing morphine sulfate, bupivacaine hydrochloride, and clonidine hydrochloride in an implantable infusion system. J Pain Symptom Manage 2004; 28: 603-11
DOI
ScienceOn
|
7 |
Nordberg G, Hedner T, Mellstrand T, Dahlströom B: Pharmacokinetic aspects of intrathecal morphine analgesia. Anesthesiology 1984; 60: 448-54
DOI
PUBMED
ScienceOn
|
8 |
Faura CC, Collins SL, Moore RA, McQuay HJ: Systematic review of factors affecting the ratios of morphine and its major metabolites. Pain 1998; 74: 43-53
DOI
ScienceOn
|
9 |
Medtronic Inc: Medtronic Synchromed II programmable infusion system clinical reference guide: pain management. 2004
|
10 |
Krames ES, Olson K: Clinical realities and economic considerations: patient selection in intrathecal therapy. J Pain Symptom Manage 1997; 14(3 Suppl): 3-13
DOI
ScienceOn
|
11 |
France JC, Jorgenson SS, Lowe TG, Dwyer AP: The use of intrathecal morphine for analgesia after posterolateral lumbar fusion: a prospective, double-blind, randomized study. Spine 1997; 22: 2272-7
DOI
ScienceOn
|
12 |
Krames ES: Intrathecal infusional therapies for intractable pain: patient management guidelines. J Pain Symptom Manage 1993; 8: 36-46
DOI
PUBMED
ScienceOn
|
13 |
Expert Working Group of the European Association for Palliative Care: Morphine in cancer pain: modes of administration. BMJ 1996; 312: 823-6
DOI
ScienceOn
|
14 |
Anderson VC, Cooke B, Burchiel KJ: Intrathecal hydromorphone for chronic nonmalignant pain: a retrospective study. Pain Med 2001; 2: 287-97
DOI
ScienceOn
|
15 |
Johnston J, Reich S, Bailey A, Sluetz J: Shiley INFUSAID Pump technology. Ann N Y Acad Sci 1988; 531: 57-65
DOI
PUBMED
ScienceOn
|
16 |
Van Dongen RT, Crul BJ, van Egmond J: Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients. Clin J Pain 1999; 15: 166-72
DOI
ScienceOn
|
17 |
Raphael JH, Southall JL, Gnanadurai TV, Treharne GJ, Kitas GD: Long-term experience with implanted intrathecal drug administration systems for failed back syndrome and chronic mechanical low back pain. BMC Musculoskelet Disord 2002; 3: 17
DOI
ScienceOn
|
18 |
Koulousakis A, Kuchta J, Bayarassou A, Sturm V: Intrathecal opioids for intractable pain syndromes. Acta Neurochir Suppl 2007; 97(Pt 1): 43-8
|
19 |
Anderson VC, Burchiel KJ: A prospective study of longterm intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery 1999; 44: 289-300
DOI
ScienceOn
|
20 |
Miele VJ, Price KO, Bloomfield S, Hogg J, Bailes JE: A review of intrathecal morphine therapy related granulomas. Eur J Pain 2006; 10: 251-61
DOI
ScienceOn
|
21 |
Seo KS, Han KR, Kim SY, Park KE, Kim C: Implantable Intrathecal drug delivery pump in complex regional pain syndrome patient: a case report. Korean J Pain 2009; 22: 74-7
DOI
|
22 |
Payne R, Inturrisi CE: CSF distribution of morphine, methadone and sucrose after intrathecal injection. Life Sci 1985; 37: 1137-44
DOI
ScienceOn
|
23 |
Pasternak GW, Bodnar RJ, Clark JA, Inturrisi CE: Morphine- 6-glucuronide, a potent mu agonist. Life Sci 1987; 41: 2845-9
DOI
ScienceOn
|
24 |
Yaksh TL, Rudy TA: Narcotic analgestics: CNS sites and mechanisms of action as revealed by intracerebral injection techniques. Pain 1978; 4: 299-359
DOI
ScienceOn
|
25 |
Ruan X: Drug-related side effects of long-term intrathecal morphine therapy, Pain Physician 2007; 10: 357-66
PUBMED
ScienceOn
|
26 |
Singh PK, Jain R, Mishra S, Kumar S, Bhatnagar S, Deo S: Management of pericatheter cerebrospinal fluid leak after intrathecal implantation of a drug delivery system. Am J Hosp Palliat Care 2008; 25: 237-9
DOI
|
27 |
Lee SJ, Nam SK, Kim JH, Kim HJ, Lee SC, Kim YC: Implantation of an intrathecal drug administration system: a report of two cases. Korean J Pain 2009; 22: 68-73
DOI
|
28 |
Auld AW, Maki-Jokela A, Murdoch DM: Intraspinal narcotic analgesia in the treatment of chronic pain. Spine 1985;10: 777-81
DOI
ScienceOn
|
29 |
Hassenbusch SJ: Cost modeling for alternate routes of administration of opioids for cancer pain. Oncology (Williston Park) 1999; 13(5 Suppl 2): 63-7
PUBMED
|
30 |
Hassenbusch SJ, Stanton-Hicks M, Covington EC, Walsh JG, Guthrey DS: Long-term intraspinal infusions of opioids in the treatment of neuropathic pain. J Pain Symptom Manage 1995; 10: 527-43
DOI
ScienceOn
|
31 |
Leavens ME, Hill CS Jr, Cech DA, Weyland JB, Weston JS: Intrathecal and intraventricular morphine for pain in cancer patients: initial study. J Neurosurg 1982; 56: 241-5
DOI
PUBMED
|
32 |
Wang JK, Nauss LA, Thomas JE: Pain relief by intrathecally applied morphine in man. Anesthesiology 1979; 50: 149-51
DOI
PUBMED
ScienceOn
|
33 |
Onofrio BM, Yaksh TL, Arnold PG: Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. Mayo Clin Proc 1981; 56: 516- 20
ScienceOn
|
34 |
Thimineur MA, Kravitz E, Vodapally MS: Intrathecal opioid treatment for chronic non-malignant pain: a 3-year prospective study. Pain 2004; 109: 242-9
DOI
ScienceOn
|
35 |
Hassenbusch SJ, Paice JA, Patt RB, Bedder MD, Bell GK: Clinical realities and economic considerations: economics of intrathecal therapy. J Pain Symptom Manage 1997; 14(3 Suppl): 36-48
DOI
ScienceOn
|
36 |
Sylvester RK, Lindsay SM, Schauer C: The conversion challenge: from intrathecal to oral morphine. Am J Hosp Palliat Care 2004; 21: 143-7
DOI
ScienceOn
|
37 |
Angel IF, Gould HJ Jr, Carey ME: Intrathecal morphine pump as a treatment option in chronic pain of nonmalignant origin. Surg Neurol 1998; 49: 92-8
DOI
ScienceOn
|
38 |
Winkelmller M, Winkelmller W: Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J Neurosurg 1996; 85: 458-67
DOI
ScienceOn
|
39 |
Rauck RL, Cherry D, Boyer MF, Kosek P, Dunn J, Alo K: Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain 2003; 4: 441-7
DOI
ScienceOn
|
40 |
Patel VB, Manchikanti L, Singh V, Schultz DM, Hayek SM, Smith HS: Systematic review of intrathecal infusion systems for long-term management of chronic non-cancer pain. Pain Physician 2009; 12: 345-60
ScienceOn
|
41 |
Medtronic Inc: Medtronic Synchromed II programmable infusion system clinical reference guide: surgical procedures. 2004
|
42 |
Kumar K, Kelly M, Pirlot T: Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: long-term benefits and efficacy. Surg Neurol 2001; 55: 79-86
DOI
ScienceOn
|
43 |
Doggrell SA: Intrathecal ziconotide for refractory pain. Expert Opin Investig Drugs 2004; 13: 875-7
DOI
ScienceOn
|
44 |
Rico RC, Hobika GH, Avellanosa AM, Trudnowski RJ, Rempel J, West CR: Use of intrathecal and epidural morphine for pain relief in patients with malignant diseases: a preliminary report. J Med 1982; 13: 223-31
PUBMED
|
45 |
Roberts LJ, Finch PM, Goucke CR, Price LM: Outcome of intrathecal opioids in chronic non-cancer pain. Eur J Pain 2001; 5: 353-61
DOI
ScienceOn
|
46 |
Smith TJ, Coyne PJ, Staats PS, Deer T, Stearns LJ, Rauck RL, et al: An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Ann Oncol 2005; 16: 825-33
DOI
ScienceOn
|
47 |
Moore A, Bullingham R, McQuay H, Allen M, Baldwin D, Cole A: Spinal fluid kinetics of morphine and heroin. Clin Pharmacol Ther 1984; 35: 40-5
DOI
ScienceOn
|
48 |
Brazenor GA: Long term intrathecal administration of morphine: a comparison of bolus injection via reservoir with continuous infusion by implanted pump. Neurosurgery 1987; 21: 484-91
DOI
PUBMED
|
49 |
Yaksh TL, Onofrio BM: Retrospective consideration of the doses of morphine given intrathecally by chronic infusion in 163 patients by 19 physicians. Pain 1987; 31: 211-23
DOI
ScienceOn
|
50 |
Belverud S, Mogilner A, Schulder M: Intrathecal pumps. Neurotherapeutics 2008; 5: 114-22
DOI
ScienceOn
|